Description: Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as transplantation, renal disease, oncology, respiratory, pain management, diabetes and cardiovascular management, gastro-intestinal care, nephrology, osteoporosis management, orthopedics, pain management, and fever; and betacoronavirus, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, hepatitis A, and varicella vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, Sputnik-V; Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc for the manufacture and supply of Azacitidine injection; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.
Home Page: www.panaceabiotec.com
B-1 Extension/G-3
New Delhi,
110044
India
Phone:
91 11 4167 9000
Officers
| Name | Title |
|---|---|
| Dr. Rajesh Jain Ph.D. | Chairman of the Board & MD |
| Mr. Sandeep Jain | Joint MD & Executive Director |
| Mr. Devender Gupta | CFO & Head of Information Technology |
| Dr. Khalid Al Syed | Chief Scientific Officer |
| Mr. Vinod Goel | Group CFO, Head of Legal, Company Secretary & Compliance Officer |
| Mr. Ankesh Jain | Whole-Time Director |
| Dr. Rajeeva Kumar Mangalum | Chief Operating Officer |
| Naresh Chand Gupta | General Manager of Accounts & Taxation |
| Mr. Ashish Jain | Chief Information Officer |
| Mr. Gurinder Pal Singh | Senior Vice President of Sales |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.2397 |
| Price-to-Sales TTM: | 4.9448 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 1936 |